Research Grade Mirikizumab(TD-HV466056) is ahumanized monoclonalantibody detectingSGRFinELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable forHuman.HighlightsMulti-Application— Validated across multiple applications.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Protein A/G purified from cell culture supernatant.
Accession
Q9NPF7
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names
LY-3074828, 1884201-71-1
Background
Mirikizumab (Eli Lilly and Company), Risankizumab (Boehringer Ingelheim and AbbVie), Tildrakizumab (Sun Pharma), Brazikumab (AstraZeneca), and Guselkumab (Janssen Biotech Inc.) are other drugs which target IL-23 and received the FDA approval for the treatment of psoriasis.
Caption
Detects IL23A in indirect ELISAs. ### Detects IL23A in indirect ELISA | SDS-PAGE for Research Grade Mirikizumab.
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询